Drug Profile
Naproxen immediate-release - Oxford Pharmascience
Alternative Names: Gastric-safe naproxen; Immediate release naproxen - Oxford Pharmasciences; OXP 005; OXPzero™ naproxenLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Oxford Pharmascience
- Class Antipyretics; Antirheumatics; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Suspended Musculoskeletal pain
Most Recent Events
- 27 Sep 2017 Suspended - Phase-I for Musculoskeletal pain (In volunteers) in United Kingdom, pending conclusion of a strategic review (PO)
- 09 Nov 2016 Oxford Pharmascience's naproxen immediate-release is available for market licensing as of 09 Nov 2016. www.oxfordpharmascience.com
- 09 Nov 2016 Oxford Pharmascience files for patent protection with UK Intellectual Property Office for OXPzero™ technology in United Kingdom